Publiziert in: Marktpuls, Unternehmen
Frei

Ypsomed and Sidekick Health launch a collaborative digital health solution for obesity management Montag, 07. April 2025 - 07:03

LOG_Ypsomed.png

Media release

Ypsomed and Sidekick Health launch a collaborative digital health solution for obesity management

Burgdorf, 07.04.2025, 7.00 a.m. – Ypsomed (SIX: YPSN) and Sidekick Health are launching an integrated digital health solution to better support people with obesity. Ypsomed's autoinjectors seamlessly integrate into Sidekick's digital health and chronic condition support app to help patients using GLP-1-based injectable therapies manage their treatment more effectively.

In this digital health solution the SmartPilot, an intelligent add-on for YpsoMate autoinjectors, is paired with the Sidekick app. This allows users, medical professionals, and pharma companies to see real-time injection data on time and date, duration, and correctness of administration, while simultaneously supporting users with wrap-around disease education and selfcare support. 

The challenge of obesity: support for a complex chronic condition
Obesity is a complex, multifaceted chronic condition that demands holistic care and affects hundreds of millions of people worldwide. Despite the transformative potential of GLP-1 therapies, many patients struggle with selfcare management. They face challenges such as managing side effects, understanding their condition, and adhering to medication titration schedules. As a result, many fail to reach their therapeutic potential, which limits the effectiveness of GLP-1 therapies. 

A tailored digital solution for obesity management 
By improving adherence and persistence, this integrated solution aims to unlock the full health potential of GLP-1 therapies, including sustained weight loss, and reductions in cardiovascular and metabolic risks. 

Key features include: 

  • Patient education: Resources to help patients better understand obesity as a condition, manage medication titration, and set realistic expectations for treatment outcomes. 
  • Lifestyle and behavioral support: Personalised, engaging content based on behavioral health principles to empower patients throughout their treatment journey, including symptom tracking, nutritional guidance, physical activity coaching, and tools to enhance sleep, and manage stress. 
  • Injection support: A dedicated injection guide designed to simplify and optimise the injection process, including a reminder function, step-by-step instructions, feedback on whether the injection has been conducted correctly, and addressing needle-related concerns. 

The solution offers a robust technical platform for pharmaceutical companies to deliver an enhanced patient experience by integrating therapy and injection procedures while supporting patient behavior tracking. Ypsomed's smart devices collect real-time adherence data, generating high-quality real-world data to optimise therapy.

"This collaboration with Sidekick Health enables us to empower patients with knowledge, real-time insights and smarter therapy management, improving long-term health outcomes. By connecting our smart injection devices, real-time data can be collected to track therapy. This allows our pharma customers to continually improve the treatment of obesity", said Ulrike Bauer, Chief Business Officer Ypsomed Delivery Systems.

"This partnership exemplifies our commitment to leveraging technology to address critical gaps in chronic condition management. Our partnership with Ypsomed underscores our shared commitment to transforming the treatment journey for people with obesity and enhancing patient outcomes," said Dr. Tryggvi Thorgeirsson, CEO of Sidekick Health. 

For more details on this collaboration and how digital health enhances the management of chronic conditions, visit https://yds.ypsomed.com/en/digital-health/therapy-management.html

Contact

Susanne Koehler, Public Relations, Ypsomed Holding AG
+41 34 424 47 32, susanne.koehler@ypsomed.com

This communication and the media material can be found at www.ypsomed.com/pressreleases

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners. Ypsomed has over 2,600 employees worldwide.

Ypsomed AG, Brunnmattstrasse 6, 3401 Burgdorf, Switzerland
info@ypsomed.com, www.ypsomed.com